Yeon Sun Lee

List of Publications by Year
in descending order

38 papers	692 citations	516710 16 h-index	580821 25 g-index
38 all docs	38 docs citations	38 times ranked	836 citing authors

#	Article	IF	Citations
1	Kappa Opioid Receptor Distribution and Function in Primary Afferents. Neuron, 2018, 99, 1274-1288.e6.	8.1	100
2	Development of Potent Î¼ and Î´ Opioid Agonists with High Lipophilicity. Journal of Medicinal Chemistry, 2011, 54, 382-386.	6.4	48
3	Development of Novel Enkephalin Analogues that Have Enhanced Opioid Activities at Both Î¼ and Î´ Opioid Receptors. Journal of Medicinal Chemistry, 2007, 50, 5528-5532.	6.4	41
4	Design and Synthesis of Novel Hydrazide-Linked Bifunctional Peptides as Î´/Î¼ Opioid Receptor Agonists and CCK-1/CCK-2 Receptor Antagonists. Journal of Medicinal Chemistry, 2006, 49, 1773-1780.	6.4	39
5	Recent Advances in the Realm of Allosteric Modulators for Opioid Receptors for Future Therapeutics. ACS Chemical Neuroscience, 2017, 8, 1147-1158.	3.5	37
6	Cyclic Opioid Peptides. Current Medicinal Chemistry, 2016, 23, 1288-1303.	2.4	36
7	A single diamagnetic catalyCEST MRI contrast agent that detects cathepsin B enzyme activity by using a ratio of two CEST signals. Contrast Media and Molecular Imaging, 2016, 11, 130-138.	0.8	32
8	Partial Retroâ^'Inverso, Retro, and Inverso Modifications of Hydrazide Linked Bifunctional Peptides for Opioid and Cholecystokinin (CCK) Receptors. Journal of Medicinal Chemistry, 2007, 50, 165-168.	6.4	29
9	Neuropathic plasticity in the opioid and non-opioid actions of dynorphin A fragments and their interactions with bradykinin B2 receptors on neuronal activity in the rat spinal cord. Neuropharmacology, 2014, 85, 375-383.	4.1	27
10	Discovery of Amphipathic Dynorphin A Analogues to Inhibit the Neuroexcitatory Effects of Dynorphin A through Bradykinin Receptors in the Spinal Cord. Journal of the American Chemical Society, 2014, 136, 6608-6616.	13.7	27
11	Brain Delivery of a Potent Opioid Receptor Agonist, Biphalin during Ischemic Stroke: Role of Organic Anion Transporting Polypeptide (OATP). Pharmaceutics, 2019, 11, 467.	4.5	27
12	Understanding the structural requirements of 4-anilidopiperidine analogues for biological activities at Î¼ and Î´ opioid receptors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 2161-2165.	2.2	26
13	New paradigms and tools in drug design for pain and addiction. AAPS Journal, 2006, 8, E450-E460.	4.4	23
14	Design and synthesis of trivalent ligands targeting opioid, cholecystokinin, and melanocortin receptors for the treatment of pain. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4080-4084.	2.2	19
15	Enkephalin-Fentanyl Multifunctional Opioids as Potential Neuroprotectants for Ischemic Stroke Treatment. Current Pharmaceutical Design, 2017, 22, 6459-6468.	1.9	19
16	Dynorphin A analogs for the treatment of chronic neuropathic pain. Future Medicinal Chemistry, 2016, 8, 165-177.	2.3	17
17	Synthesis and evaluation of bivalent ligands for binding to the human melanocortin-4 receptor. Bioorganic and Medicinal Chemistry, 2014, 22, 6360-6365.	3.0	16
18	Biphalin: The Foundation of Bivalent Ligands. Current Medicinal Chemistry, 2016, 23, 3267-3284.	2.4	13

#	Article	IF	Citations
19	Structureâ€“activity relationships of non-opioid [des-Arg7]-dynorphin A analogues for bradykinin receptors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4976-4979.	2.2	11
20	Modification of amphipathic non-opioid dynorphin A analogues for rat brain bradykinin receptors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 30-33.	2.2	11
21	Structureâ€“Activity Relationships of [des-Arg⁷]Dynorphin A Analogues at the Î¹ Opioid Receptor. Journal of Medicinal Chemistry, 2016, 59, 10291-10298.	6.4	11
22	Î²IV-spectrin as a stalk cell-intrinsic regulator of VEGF signaling. Nature Communications, 2022, 13, 1326.	12.8	11
23	Opioid and melanocortin receptors: Do they have overlapping pharmacophores?. Biopolymers, 2008, 90, 433-438.	2.4	10
24	Regulation of mitochondrial fission by GIPC-mediated Drp1 retrograde transport. Molecular Biology of the Cell, 2022, 33, mbcE21060286.	2.1	10
25	Discovery of Stable Non-opioid Dynorphin A Analogues Interacting at the Bradykinin Receptors for the Treatment of Neuropathic Pain. ACS Chemical Neuroscience, 2016, 7, 1746-1752.	3.5	7
26	Cyclic biphalin analogues with a novel linker lead to potent agonist activities at mu, delta, and kappa opioid receptors. Bioorganic and Medicinal Chemistry, 2018, 26, 3664-3667.	3.0	6
27	Preclinical Assessment of the Analgesic Pharmacology of NKTR-181 in Rodents. Cellular and Molecular Neurobiology, 2021, 41, 949-960.	3.3	6
28	Time-Dependent Changes in Protein Composition of Medial Prefrontal Cortex in Rats with Neuropathic Pain. International Journal of Molecular Sciences, 2022, 23, 955.	4.1	6
29	Cyclic non-opioid dynorphin A analogues for the bradykinin receptors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5513-5516.	2.2	5
30	Gramâ€Scale Preparation of Câ€Terminalâ€Modified Enkephalin Analogues by Typical Liquidâ€Phase Peptide Synthesis. Current Protocols in Protein Science, 2019, 98, e97.	2.8	5
31	Multifunctional Enkephalin Analogs with a New Biological Profile: MOR/DOR Agonism and KOR Antagonism. Biomedicines, 2021, 9, 625.	3.2	5
32	Design, synthesis, and biological evaluation of a series of bifunctional ligands of opioids/SSRIs. Bioorganic and Medicinal Chemistry, 2015, 23, 1251-1259.	3.0	4
33	Chiral Effect of a Phe Residue in Position 3 of the Dmt¹-<scp>l</scp>(or) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 1 Letters, 2013, 4, 656-659.	2.8	3
34	Various modifications of the amphipathic dynorphin <scp>A</scp> pharmacophore for rat brain bradykinin receptors. Chemical Biology and Drug Design, 2016, 88, 615-619.	3.2	2
35	Blockade of non-opioid excitatory effects of spinal Dynorphin A at bradykinin receptors. Receptors & Clinical Investigation, 2015, 2, .	0.9	2
36	C-terminal modified Enkephalin-like tetrapeptides with enhanced affinities at the kappa opioid receptor and monoamine transporters. Bioorganic and Medicinal Chemistry, 2021, 51, 116509.	3.0	1

#	Article	IF	Citations
37	High Affinity Binding of Dynorphin Aâ€(2â€“13) at the Bradykininâ€2 Receptor. FASEB Journal, 2012, 26, 836.2.	0.5	0
38	TY032, a potent opioid agonist/neurokinin 1 antagonist produces analgesia without motor impairment or sedation. FASEB Journal, 2013, 27, 887.3.	0.5	0